

Effect of Test Parameters on Material-mediated Hemolysis Using the ASTM F756-17 Standard Test Method

Richard Malinauskas¹, Cindy Liu², Shelby Skoog³, Qijin Lu¹

¹Div. of Applied Mechanics/OSEL, ²University of Maryland, ³Div. of Biology, Chemistry, and Materials Science/OSEL
Center for Devices and Radiological Health, Office of Science and Engineering Laboratories (OSEL)




FDA

Abstract

Background: To ensure the safety of blood-contacting medical devices (e.g., catheters, blood pumps), FDA works with industry to develop standard procedures for pre-market hemocompatibility testing. **Purpose:** To improve the ASTM F756-17 testing standard for assessing damage to red blood cells (hemolysis) by device materials, we investigated the impact of multiple test parameters: positive control materials, test volume (8 mL vs 2 mL), and incubation time. **Methods:** Rabbit blood pooled from 3 donors was diluted with Ca/Mg-free phosphate buffered saline (CMF-PBS) to a total hemoglobin concentration of 125 mg/dL in vials containing materials. Test materials, including possible positive (nitrile gloves, Buna-N rubber, latex) and negative controls (high-density polyethylene [HDPE]), at a surface area to CMF-PBS volume ratio of 3 or 6 cm²/mL (based on material thickness per ASTM F756) were exposed to either 2 or 8 mL of the diluted blood and tested in triplicate. Dimethyl sulfoxide (DMSO) at various concentrations in CMF-PBS was also tested with diluted blood. Vials were incubated at 37 °C for up to 3 hrs. Treated blood was centrifuged and the supernatant assayed for free hemoglobin released from damaged red blood cells using a cyanmethemoglobin reagent and spectrophotometer. **Results:** Average %hemolysis was <1% for the negative control HDPE, 5% to 89% for nitrile gloves (varying by brand), and 4-7% for Latex and Buna-N rubbers. Reducing the test fluid volume and material size by a factor of 4 did not significantly change the %hemolysis results for any sample type. The %hemolysis increased with increasing concentration of DMSO and test incubation time for all tested materials. **Conclusions:** HDPE met the ASTM F756 criterion as a negative control material as it reproducibly caused <2% hemolysis, while only DMSO (at concentration ≥ 15%) and one brand of nitrile glove were suitable positive controls consistently causing >5% hemolysis. Importantly, reducing the test sample volume by a factor of 4 allows less material to be required in the test without impacting the results. As hemolysis is time-dependent, incubation should adhere to the standard specified duration of 3 hrs. **These study results will help to revise the ASTM F756-17 testing standard.**

Introduction

Hemolytic materials in blood-contacting devices can lead to hemoglobin being released from compromised red blood cell membranes (**Figure 1**).



- Free, unbound hemoglobin is vulnerable to oxidation reactions that can cause vascular and renal damage.
- The ASTM F756-17 standard has been used for over 20 years to determine the hemolytic potential (% hemolysis) of various materials by quantifying released supernatant hemoglobin.

$$\% \text{ Hemolysis} = \frac{\text{Supernatant free hemoglobin}}{\text{Total hemoglobin}} \times 100\%$$

- As medical device manufacturers and testing labs sometimes deviate from the standard ASTM F756-17 protocol, variations to the test methods are being assessed to determine factors that may impact the hemolysis levels and to improve the standard.

Materials and Methods

ASTM F756-17 Standard Protocol

Blood and test article preparation:

- Citrate anticoagulated rabbit blood pooled equally from 3 donors was diluted to 10 mg/mL total hemoglobin using calcium and magnesium-free phosphate buffered saline (CMF-PBS).
- Solid test articles with a surface area of 42 cm² or 21 cm² (depending on thickness) were dip-rinsed in PBS before being added to test tubes.
- For DMSO, stock solution was diluted with PBS and added to test tubes.
- 7 mL of PBS and 1 mL of diluted rabbit blood were pipetted into test tubes.

Incubation and sample collection:

- Samples incubated in water bath at 37 °C for 3 hrs with 3 gentle inversions every 0.5 hrs. Afterwards, treated blood samples centrifuged and supernatant collected.

Analysis:

- Cyanmethemoglobin method was used by diluting supernatant with Drabkin's reagent.
- Absorbance measured on plate reader at 540 nm.
- A hemoglobin concentration calibration curve was used to quantify the free hemoglobin in the supernatant.

Variations to Standard Testing Protocol

- Effect of PBS/blood volume reduction:** Reduced the PBS/blood volume and surface area of test articles by a factor of 4 (i.e., 8 ml to 2 ml).
- Time course of hemolysis:** Measured hemolysis in 45-min increments up to 3 hrs.
- Effect of glove sample washing:** Washed NG in ultrapure water at 60 RPM, 37 °C for 48 hrs (changed water at 24 hrs).




Figure 3. Test materials in 2 mL reduced volume testing. (Left to right: DMSO, latex, NG #4, NG #2, HDPE, CMF-PBS).

| Nitrile Gloves (NG) from 4 manufacturers |
|--|
| Buna-N (Nitrile Rubber) |
| Latex Sheet |
| DMSO (Dimethyl Sulfoxide) |
| HDPE (High-density Polyethylene) |




Figure 2. Test materials in 8 mL standard volume. (Left to right: NG, Buna-N, HDPE)




Figure 4. Supernatant containing free hemoglobin after exposure to DMSO at various concentrations (Left to right: 10%, 12.5%, 15%, 17.5%, 20%).

Results and Discussion

Positive Control Identification

According to ASTM F756-17, positive controls should reproducibly cause >5% hemolysis, while negative controls should cause <2% hemolysis. Different brands of NG produced different levels of hemolysis. Increasing concentration of DMSO caused corresponding increases in % hemolysis. HDPE was a consistent negative control material producing <2% hemolysis in all test conditions.




Figure 5. %Hemolysis comparison for all tested materials. Samples tested in triplicate on each day.




Figure 6. %Hemolysis for different DMSO concentrations.

Table 2. Summary of material %hemolysis (mean ± SD).

| Material | % Hemolysis |
|------------|-------------|
| NG #1 | 93.3 ± 8.6 |
| NG #2 | 6.3 ± 4.2 |
| NG #4 | 6.5 ± 2.9 |
| Latex | 5.9 ± 1.7 |
| Buna-N | 3.9 ± 2.2 |
| 17.5% DMSO | 31.4 ± 6.2 |
| HDPE | 1.2 ± 0.6 |

Effect of CMF-PBS/Blood Volume Reduction

No significant difference in %Hemolysis test results for any material ($p > 0.05$) when reducing the CMF-PBS/blood volume by a factor of 4.




Figure 7. Comparison of %hemolysis when using 8 mL (standard) versus 2 mL (reduced) CMF-PBS/ blood volume.

Effect of Incubation Time

Rates of hemolysis varied for different materials tested, which supports the 3-hr study endpoint in the standard.




Figure 8. Non-blank-corrected %hemolysis at 45-min increments during incubation (average from 3 separate trials). Each material was tested in 3 replicates at the 3-hr endpoint and 2 replicates at all other timepoints.

Effect of Washing Nitrile Gloves

Hemolysis caused by washed nitrile gloves was lower compared to their unwashed counterparts.




Figure 9. %Hemolysis comparison for washed and unwashed NG.

Conclusions

- HDPE was a consistent negative control (%hemolysis < 2%) for all conditions. Only DMSO (at concentration ≥ 15%) and one nitrile glove (NG #1) were suitable positive controls consistently causing >5% hemolysis.
- Use of reduced CMF-PBS/Blood volume of 2 mL (instead of standard 8 mL) did not impact the hemolysis results and could benefit manufacturers by decreasing the amount of device materials required for the test.
- As hemolysis is time-dependent, incubation should adhere to the standard specified duration of 3 hrs.
- Hemolysis caused by nitrile gloves is likely due to water-soluble chemicals, since washed gloves had lower hemolysis compared to unwashed ones.

Acknowledgement

This project was supported in part by an appointment to the Research Participation Program at the CDRH, U.S. FDA administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA.